ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Imfinzi shows sustained OS benefit in first-line ES-SCLC in CASPIAN trial
June 03, 2020Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin ... -
Imfinzi Confirmed Sustained Overall Survival Benefit in Small Cell Lung Cancer Trial
March 18, 2020High-level results from the final analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies confirmed a sustained.
Pharma Sources Insight January 2025
